Goat F(ab')2 Anti-Human IgG (Fab')2 (HRP) (ab98535)
Key features and details
- Goat F(ab')2 Anti-Human IgG (Fab')2 (HRP)
- Conjugation: HRP
- Host species: Goat
- Isotype: IgG
- Suitable for: ICC, IHC-P, ELISA, WB
Related conjugates and formulations
Overview
-
Product name
Goat F(ab')2 Anti-Human IgG (Fab')2 (HRP)
See all IgG secondary antibodies -
Host species
Goat -
Target species
Human -
Tested applications
Suitable for: ICC, IHC-P, ELISA, WBmore details -
Conjugation
HRP
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 6.8
Constituents: 0.2% BSA, 0.05% CMIT/MIT based preservative -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
This antibody was isolated by affinity chromatography using antigen coupled to agarose beads. F(ab')2 fragments were generated using a pepsin digestion. Fc fragments and whole IgG molecules have been removed. Fragments were conjugated to Horse Radish Peroxidase. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab98535 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC |
Use at an assay dependent dilution.
|
|
IHC-P |
1/200 - 1/2000.
|
|
ELISA |
1/10000 - 1/100000. (Primary).
|
|
WB | (1) |
1/2000 - 1/25000. (Colorimetric: 1/2000 - 1/20000, Chemiluminescent: 1/5000 - 1/25000).
|
Notes |
---|
ICC
Use at an assay dependent dilution. |
IHC-P
1/200 - 1/2000. |
ELISA
1/10000 - 1/100000. (Primary). |
WB
1/2000 - 1/25000. (Colorimetric: 1/2000 - 1/20000, Chemiluminescent: 1/5000 - 1/25000). |
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (7)
ab98535 has been referenced in 7 publications.
- Passariello M et al. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. Sci Rep 11:11046 (2021). PubMed: 34040046
- Tan XW et al. Rapid and specific detection of oxidized LDL/ß2GPI complexes via facile lateral flow immunoassay. Heliyon 6:e04114 (2020). PubMed: 32551380
- Seabright GE et al. Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. Structure 28:897-909.e6 (2020). PubMed: 32433992
- Passariello M et al. Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. Cancers (Basel) 12:N/A (2020). PubMed: 32781690
- Passariello M et al. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. Sci Rep 9:13125 (2019). PubMed: 31511565
- Sasso E et al. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. MAbs 10:1060-1072 (2018). PubMed: 29995563
- Oaks M et al. Xenoreactive antibodies and latent fibrin formation in VAD and cardiac transplant recipients can confound the detection and measurement of anti-AT1R antibodies. Am J Transplant 18:2763-2771 (2018). PubMed: 29603642